Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Evaluation of the Effect of AVE0657 in Cheynes-Stokes Breathing Syndrome Patients

Phase 2

Terminated

Conditions: Heart Failure
Sleep Apnea Syndromes
Cheyne-Stokes Respiration

Interventions: Drug: AVE0657
Drug: placebo

First Posted Date: 2008-06-10

Last Posted Date: 2009-05-01

Lead Sponsor: Sanofi

Target Recruit Count: 8

Registration Number: NCT00694720

Locations: 🇪🇸
Sanofi-Aventis Administrative Office, Barcelona, Spain

Study to Optimize Insulin Treatment by Basal Regimen With Insulin Glargine in Type-2-Diabetic Patients Previously Uncontrolled on Premixed Insulin

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Insulin Glargine

First Posted Date: 2008-06-09

Last Posted Date: 2011-01-25

Lead Sponsor: Sanofi

Target Recruit Count: 313

Registration Number: NCT00693771

Locations: 🇨🇳
Sanofi-Aventis Administrative Office, Shanghai, China

Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid Tumors

Phase 1

Completed

Conditions: Cancer
Non-small Cell Lung Cancer

Interventions: Drug: XL147 (SAR245408)
Drug: Erlotinib

First Posted Date: 2008-06-06

Last Posted Date: 2012-03-23

Lead Sponsor: Sanofi

Target Recruit Count: 35

Registration Number: NCT00692640

Locations: 🇺🇸
Investigational Site Number 1214, Nashville, Tennessee, United States

Effect of Rimonabant and Metformin Combination on Glycemic Control in Patients With Type 2 Diabetes

Phase 3

Terminated

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo (for Rimonabant)
Drug: Rimonabant
Drug: Metformin

First Posted Date: 2008-06-04

Last Posted Date: 2016-05-18

Lead Sponsor: Sanofi

Target Recruit Count: 403

Registration Number: NCT00690456

Locations: 🇺🇦
Sanofi-Aventis Administrative Office, Kiev, Ukraine

Docetaxel in Node Positive Adjuvant Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: 5-fluorouracil
Drug: Docetaxel
Drug: Doxorubicin
Drug: Cyclophosphamide

First Posted Date: 2008-06-03

Last Posted Date: 2011-02-16

Lead Sponsor: Sanofi

Target Recruit Count: 1491

Registration Number: NCT00688740

Locations: 🇮🇱
sanofi-aventis Administrative office, Natanya, Israel
🇬🇧
Sanofi-aventis adminsitrative office, Guildford Surrey, United Kingdom
🇸🇪
Sanofi-Aventis Administrative Office, Bromma, Sweden

and more 1 locations